A new NSCLC asset must displace pembrolizumab's estimated 52% first-line share, ahead of its 2028 patent expiry, in a market where only 46% of patients ever receive the full guideline biomarker panel.
Four approved IO agents already divide first-line NSCLC into three PD-L1-defined cohorts. Pembrolizumab controls the PD-L1 >=50% monotherapy setting and much of the chemo-combination space through five years of clinical and commercial precedent, an estimated 52% share, ahead of a 2028 US patent expiry that opens the first biosimilar entry window into the dominant cohort. Nivolumab plus ipilimumab (~18%), atezolizumab (~8%), and durvalumab (~12%, largely Stage III consolidation) hold the remainder. A new entrant is not launching into an open market; it is launching into a share position that took five years and three separate label expansions to build, and the coverage precedent those five years wrote is the standard a new asset will be judged against, not its own trial design.
That coverage precedent bites twice. First, structurally: all four approved agents are physician-administered biologics reimbursed through Medicare Part B buy-and-bill at ASP+6%, not the Part D formulary architecture, so the access fight happens at the PD-L1 assay-testing and prior-authorization layer, not the pharmacy benefit tier. Second, practically: only 46% of US patients receive all five guideline-recommended biomarker tests before first-line therapy begins (MYLUNG, 2022), which means a new biomarker-defined asset's near-term addressable pool is capped well below the diagnosed population until testing penetration improves, regardless of how compelling its trial data is. The window to shape the payer coverage conversation is 12 to 18 months before approval, not at launch.
Exhibit — the NSCLC first-line incumbent map a new entrant is measured against.
| Agent (Sponsor) | PD-L1 Threshold | Pivotal Trial | Access Channel | Share Est. |
|---|---|---|---|---|
| Pembrolizumab (Merck) | >=50% (mono) / >=1% (combo) | KEYNOTE-024, 189, 407 | Part B buy-and-bill, ASP+6% | ~52% |
| Nivolumab + Ipilimumab (BMS) | Any (TMB signal) | CheckMate-9LA, 227 | Part B buy-and-bill, ASP+6% | ~18% |
| Atezolizumab (Roche/Genentech) | Any (SP142 IHC) | IMpower110, IMpower150 | Part B buy-and-bill, ASP+6% | ~8% |
| Durvalumab (AstraZeneca) | Stage III: any / 1L: any (LAURA) | PACIFIC, LAURA (2024) | Part B buy-and-bill, ASP+6% | ~12% |
Sources: FDA prescribing information (pembrolizumab, nivolumab + ipilimumab, atezolizumab, durvalumab). KEYNOTE-024: Reck et al., NEJM 2016, PMID 27718847. KEYNOTE-189: Gandhi et al., NEJM 2018, PMID 29658856. KEYNOTE-407: Paz-Ares et al., NEJM 2018, PMID 30280635. CheckMate-9LA: Reck et al., Lancet Oncol 2021, PMID 34126067. CheckMate-227: Hellmann et al., NEJM 2018, PMID 29658845. IMpower110: Spigel et al., NEJM 2021, PMID 34280284. IMpower150: Socinski et al., NEJM 2018, PMID 29863955. PACIFIC: Antonia et al., NEJM 2017, PMID 28885881. Prescribing share estimates derived from IQVIA MIDAS analogs.
Five questions. Each section is built to answer one of them.
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- Cohort-by-cohort share and evidence map across the four approved agents
- The 2028 patent-expiry window and what it opens for a biosimilar or differentiated entrant
- Which PD-L1 cohort carries the least entrenched incumbent
Delivers
- The KEYNOTE/CheckMate/IMpower/PACIFIC coverage precedent new entrants are evaluated against
- PD-L1 assay-tier mapping (22C3, no threshold, SP142) and the testing burden each implies
- Why the 46% full-panel testing rate caps near-term addressable volume for a biomarker-gated asset
Delivers
- The ~13,000-oncologist concentrated prescriber base and account-tiering logic
- Part B buy-and-bill economics versus Part D for oral targeted agents, and the field-role split this requires
- Why account depth, not prescriber reach, is the correct commercial model
Delivers
- Non-responder and progression-after-IO cohort mapping
- Biomarker gaps (ROS1, KRAS G12C) with less entrenched first-line competition
- MOA-alignment assessment against the current four-agent landscape
Delivers
- Three-scenario share model bounded by testing-rate and PA-timeline sensitivity
- Ranked assumption drivers behind the variance
- A pre-approval payer-engagement timeline built to the 12-18 month window
Scoped to your asset's target cohort and proposed label — not the disease in aggregate.
Scope Your WorkWhat's inside
- Why pembrolizumab's ~52% share and five years of precedent set the bar, not the disease in aggregate
- The 2028 patent-expiry window and the 46% biomarker-testing ceiling that bounds near-term addressable volume
- Cohort-by-cohort positioning: pembrolizumab, nivolumab+ipilimumab, atezolizumab, durvalumab
- Pivotal-trial comparison (OS, PFS, ORR) across KEYNOTE, CheckMate, IMpower, PACIFIC, LAURA
- Why only 46% of patients receive the full five-biomarker panel before first-line therapy
- PD-L1 assay-tier mapping (22C3 TPS>=50%, no threshold, SP142) and its effect on addressable volume
- Why all four approved 1L agents route through Medicare Part B at ASP+6%, not Part D
- Coverage criteria by agent and the evidence standard payers will apply to a new entrant
- Non-responder and progression-after-IO cohort mapping
- Biomarker segments (ROS1, KRAS G12C) with less entrenched first-line competition
- The ~13,000-oncologist concentrated, account-based prescriber landscape
- Part B versus Part D field-role split for infused versus oral entrants
- Three patient-capture scenarios (conservative, base, aggressive), built by cohort, not in aggregate
- The inputs that drive variance: testing penetration, label scope, payer timeline, competitive response
- Payer conversations that must begin 12-18 months pre-approval to avoid formulary delay
- Decisions contingent on label scope, trial outcomes, or the 2028 LOE window
Included with every brief
Every figure is live-sourced before delivery. If a number cannot be verified, it does not appear.
Prepared by MoatRx analysts.
The IO competitive landscape is a field where AI confidently reproduces outdated trial data, superseded payer policies, and retracted subgroup analyses. AXLRx uses none of its own memory as a source. Every figure your team receives is verified against a live document at the time of writing.
A wrong number in front of your payer or your leadership team is not recoverable in the same meeting.
- Every claim cited to a live PMID, ClinicalTrials.gov ID, or URL at point of writing, uncited claims are dropped, not estimated
- Incumbent share, trial, and testing-rate figures verified against FDA prescribing information and the primary NEJM/Lancet Oncology publications
- Independent audit pass after generation, broken links, unsourced claims, and numeric inconsistencies flagged before delivery
- Drop gate: any figure that cannot clear the above is removed. No confidence tiers. No exceptions.
Frequently asked questions
Tell us your asset. Your team has the launch-readiness intelligence in 72 hours.
We build from your asset's clinical profile, mechanism, biomarker strategy, proposed label, and target cohort. Scope confirmation takes one call.
Drug, mechanism, proposed indication, target cohort, geography. Five minutes via the intake form.
We confirm scope with your team, clarify ambiguities, and lock delivery timing.
PDF intelligence document, Excel model, and optional executive deck, with a 30-minute readout call included.